Vertex Pharmaceuticals Incorporated
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $6.14B | $5.49B | $5.08B | $4.94B | $4.97B | $4.67B | $4.57B | $5.24B |
| Accounts Receivable | $2.13B | $2.00B | $2.05B | $1.95B | $1.89B | $1.81B | $1.61B | $1.75B |
| Inventory | $1.77B | $1.77B | $1.69B | $1.63B | $1.50B | $1.36B | $1.21B | $1.08B |
| Total Current Assets | $12.54B | $11.73B | $11.20B | $10.57B | $10.43B | $10.01B | $9.60B | $9.80B |
| Property, Plant & Equipment | — | — | — | — | — | — | — | — |
| Goodwill | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B |
| Intangible Assets (Excl. Goodwill) | $412.8M | $418.5M | $424.2M | $429.8M | $435.5M | $441.2M | $825.9M | $831.6M |
| Total Assets | $27.42B | $26.48B | $25.64B | $24.86B | $24.04B | $22.88B | $22.53B | $22.24B |
| Liabilities | ||||||||
| Accounts Payable | $429.5M | $489.3M | $461.7M | $420.3M | $442.3M | $445.0M | $413.0M | $395.8M |
| Total Current Liabilities | $3.94B | $3.88B | $3.86B | $4.48B | $4.14B | $3.78B | $3.56B | $3.97B |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $7.18B | $7.12B | $6.98B | $7.54B | $6.86B | $6.38B | $6.12B | $6.61B |
| Stockholders' Equity | ||||||||
| Retained Earnings | $15.69B | $14.59B | $13.56B | $12.37B | $11.29B | $10.25B | $9.61B | $8.69B |
| Total Stockholders' Equity | $20.25B | $19.36B | $18.67B | $17.32B | $17.18B | $16.50B | $16.41B | $15.63B |